刘文婧
学历：医学博士
职称：副研究员
邮箱：lwj9149@163.com
通讯地址：云南省昆明市呈贡区雨花街道春融西路1168号
邮编：650500
简历
2010.09-2014.06, 鲁东大学，生命科学学院，生物科学，理学学士
2014.09-2017.06, 昆明理工大学，医学院，细胞生物学，理学硕士
2017.09-2022.06, 中国科学院大学，基础医学（病理学与病理生理学），医学博士
2022.08-2024.08, 昆明医科大学第三附属医院，临床医学，博士后
2025.03-至今, 昆明医科大学，生物医学工程研究院, 助理研究员
研究方向
主要集中在蛋白质翻译后修饰和DNA损伤应答与肿瘤放化疗抵抗。肿瘤对放化疗的耐受性是肿瘤学研究中的核心问题，也是现代肿瘤生物学研究的重要方向。过度激活的DNA损伤应答是导致肿瘤细胞对放射化疗抵抗的关键分子机制之一。解析DNA损伤应答的动态平衡失调的分子机制，是理解肿瘤发生放化疗耐受的基础。同时，DNA损伤应答信号的传导主要依赖于蛋白质的翻译后修饰，如磷酸化、泛素化和乳酸化等相关的可逆修饰，以实现DNA损伤蛋白质的有序连接。围绕DNA损伤修复应答失调介导的肿瘤放化疗抵抗这一核心科学问题，深入研究蛋白质的翻译后修饰介导的DNA损伤应答分子调控网络在肿瘤抵抗放化疗中的作用机制，发现新的肿瘤治疗靶点。并基于已识别的靶点筛选小分子化合物或小肽，以期为肿瘤的放化疗耐受提供新的治疗手段。
承担科研项目
1.国家自然科学基金委员会，国家自然科学基金青年基金项目，82403795， BRCC3通过稳定EGR1增强乳腺癌放疗抵抗的功能和机制研究，2025.01至2027.12，30万元，在研，主持。
2.中国博士后科学基金会，中国博士后科学基金面上项目，2023M731448， RNF126对睾丸精子发生的分子机制研究 ，2023.06至2025.05，8万元，结题，主持。
3.科技创新2030—“癌症、心脑血管、呼吸和代谢性疾病防治研究”重大专项，2023ZD0502201，2024.08至2028.07，4000万元，在研，参与（骨干成员）。
4.国家自然科学基金委员会，国家自然科学基金重点项目，82430084， E3泛素连接酶BCA2调控乳腺发育和促乳腺癌进展的功能和机制研究及靶向策略探索， 2025.01至2029.12，230万元，在研，参与。
研究成果（论文、专利、专著等）
主要论文
1. Wenjing Liu; Min Zheng; Rou Zhang; Qiuyun Jiang; Guangshi Du; Yingying Wu; Chuanyu Yang; Fubing Li; Wei Li; Luzhen Wang; Jiao Wu; Lei Shi; Wenhui Li; Kai Zhang; Zhongmei Zhou; Rong Liu; Yingzheng Gao; Xinwei Huang; Songqing Fan; Xu Zhi; Dewei Jiang; Ceshi Chen ; RNF126‐Mediated MRE11 Ubiquitination Activates the DNA Damage Response and Confers Resistance of Triple‐Negative Breast Cancer to Radiotherapy; Advanced Science; 2023; 10(5): 2203884 (IF=14.1)
2. Wenjing Liu#; Xiya Sun#; Fubing Li#; Qiuyun Jiang; Jianting An; Yingying Wu; Jingyi Yang; Meng Qin; Yuxin Zhao; Yongjia Tang; Tingyue Wu; Zhiqiang Yan; Dewei Jiang; Rong Liu; Wenhui Li*; Xu Zhi*; Ceshi Chen*; An essential role of the E3 ubiquitin ligase RNF126 in ensuring meiosis I completion during spermatogenesis; Journal of Advanced Research; 2024 (IF=11.4)
3. Hongyan Zhang; Longlong Zhang; Yuna He; Dewei Jiang; Jian Sun; Qianmei Luo; Huichun Liang; Tiantian Wang; Fubing Li; Yu Tang; Zimo Yang;Wenjing Liu*; Yu Rao*; Ceshi Chen* PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer; Cancer Letters; 2024; 598:217112 (IF=9.1)
4. Min Zheng#;Wenjing Liu#; Rou Zhang; Dewei Jiang; Yujie Shi; Yingying Wu; Fei Ge*; Ceshi Chen*; E3 ubiquitin ligase BCA2 promotes breast cancer stemness by up-regulation of SOX9 by LPS; International Journal of Biological Sciences; 2024; 20(7), 2686-2697 (IF=8.3)
5. Maobo Huang#;Wenjing Liu#; Zhuo Cheng; Fubing Li; Yanjie Kong; Chuanyu Yang; Yu Tang; Dewei Jiang; Wenhui Li; Yudie Hu; Jinhui Hu*; Pematenzin Puno*; Ceshi Chen*; Targeting the HECTD3-p62 axis increases the radiosensitivity of triple negative breast cancer cells; Cell Death Discovery; 2024 (IF=6.1)
6.Hongyan Zhang#;Wenjing Liu#; Yingying Wu*; Ceshi Chen*; USP3: Key deubiquitylation enzyme in human diseases; Cancer Science; 2024 ;115(7), 2094-2106 (IF=5.5)
7.Tingyue Wu#;Wenjing Liu#; Hui Chen#; Lei Hou; Wenlong Ren; Longlong Zhang ; Jinhui Hu ; Haijun Chen; Ceshi Chen. Toxoflavin analog D43 exerts antiproliferative effects on breast cancer by inducing ROS-mediated apoptosis and DNA damage. Scientific Reports, 2024, 14(1): 4008 (IF=4.9)
8.Liu Wenjing#; Lu Xiaoqing#; Shi Peiguo#; Yang Guangxi; Zhou Zhongmei; Li Wei; Mao Xiaoyun; Jiang Dewei; Chen Ceshi ; TNF-alpha increases breast cancer stem-like cells through up-regulating TAZ expression via the non-canonical NF-kappa B pathway, Scientific Reports, 2020, 10(1):1804 (IF=4.9)
9.Jian Sun#;Wenjing Liu#; Yongbo Guo; Hailin Zhang; Dewei Jiang; Ying Luo; Rong Liu; Ceshi Chen ; Characterization of tree shrew telomeres and telomerase, Journal of Genetics and Genomics, 2021, 48(7): 631 (IF=5.751)
其他工作
1. Fubing Li; Huichun Liang; Hua You; Ji Xiao; Houjun Xia; Xi Chen; Maobo Huang; Zhuo Cheng; Chuanyu Yang;Wenjing Liu; Hailin Zhang; Li Zeng; Yingying Wu; Fei Ge; Zhen Li; Wenhui Zhou; Yi Wen; Zhongmei Zhou; Rong Liu; Dewei Jiang; Ni Xie; Bin Liang; Zhenzhen Liu; Yanjie Kong; Ceshi Chen; Targeting HECTD3-IKKα axis inhibits inflammation-related metastasis; Signal Transduction and Targeted Therapy; 2022; 7: 264 (IF=38.1)
2. Jiao Wu; Sai-Ching Jim Yeung; Sicheng Liu; Aiham Qdaisat; Dewei Jiang; Wenli Liu; Zhuo Cheng;Wenjing Liu; Haixia Wang; Lu Li; Zhongmei Zhou; Rong Liu; Chuanyu Yang; Ceshi Chen; Runxiang Yang; Cyst(e)ine in nutrition formulation promotes colon cancer growth and chemoresistance by activating mTORC1 and scavenging ROS; Signal Transduction and Targeted Therapy; 2021; 6: 188 (IF=18.19)
3. Yaxun Guo#; Yuzhan Li#; Zhongmei Zhou#; Lei Hou;Wenjing Liu; Wenlong Ren; Dazhao Mi; Jian Sun; Xueqin Dai; Yingying Wu; Zhuo Cheng; Tingyue Wu; Qianmei Luo; Cong Tian; Fubing Li*; Zhigang Yu*; Yihua Chen*; Ceshi Chen*; Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer; Journal of Experimental & Clinical Cancer Research; 2024; 43: 314 (IF=11.2)
4. Wenlong Ren#; Huichun Liang#; Jian Sun; Zhuo Cheng;Wenjing Liu; Yingying Wu; Yujie Shi; Zhongmei Zhou; Ceshi Chen; TNFAIP2 promotes HIF1α transcription and breast cancer angiogenesis by activating the Rac1-ERK-AP1 signaling axis; Cell Death & Disease; 2024; 15: 821 (IF=9.0)
5. Luzhen Wang#; Dazhao Mi#; Jinhui Hu#;Wenjing Liu; Yi Zhang; Chunyan Wang; Yihua Chen; Ceshi Chen; A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-MKK4-p38 axis in triple negative breast cancer; Cancer Letters; 2023; 555: 216049 (IF=9.1)
6.Jia He#; Luzhen Wang#; Dazhao Mi; Tian Guan;Wenjing Liu; Peng He; Haijun Gu; Yuzhan Li; Yangrui Peng; Ai-Qun Jia; Ceshi Chen*; Yihua Chen*; Discovery of Pyrimidinediamine Derivatives as Potent Methuosis Inducers for the Treatment of Triple-Negative Breast Cancer; Journal of Medicinal Chemistry; 2023; 66(11) (IF=6.3)
7. Yanjie Kong#; Tianlong Lan#; Luzhen Wang#; Chen Gong; Wenxin Lv; Hailin Zhang; Chengang Zhou; Xiuyun Sun;Wenjing Liu; Haihui Huang; Xin Weng; Chang Cai; Wenfeng Peng; Meng Zhang; Dewei Jiang; Chuanyu Yang; Xia Liu; Yu Rao; Ceshi Chen; BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression; Oncogene; 2024; 43: 2914–2926 (IF=9.9)
受邀为Cancer Lett、Int J Biol Sci、Breast Cancer Research和npj Precision Oncology等期刊审稿人。
